- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody–Drug Conjugates: The Last Decade
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 13, Issue 9, Pages 245
Publisher
MDPI AG
Online
2020-09-14
DOI
10.3390/ph13090245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Les immuno-conjugués en oncologie
- (2020) Alain Beck et al. M S-MEDECINE SCIENCES
- Les immunoconjugués en oncologie
- (2020) Alain Beck et al. M S-MEDECINE SCIENCES
- Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
- (2019) Alain Beck et al. Expert Review of Proteomics
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- THE ANTI-CD25 ANTIBODY-DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT-301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
- (2019) F. Spriano et al. HEMATOLOGICAL ONCOLOGY
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2019) Brad S. Kahl et al. CLINICAL CANCER RESEARCH
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
- (2018) Philip E. Brandish et al. BIOCONJUGATE CHEMISTRY
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
- (2018) Yiwen You et al. DRUG DELIVERY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France
- (2018) Camille Martin et al. mAbs
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody–drug conjugates
- (2018) Francesca Bryden et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway
- (2018) Sauveur Juliette et al. Oncotarget
- Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro
- (2018) Nicolas Aubrey et al. BIOCONJUGATE CHEMISTRY
- Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study
- (2018) Anton Hagenbeek et al. HAEMATOLOGICA
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
- (2017) Nicolas Joubert et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins
- (2017) Jared L. Spidel et al. mAbs
- A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
- (2017) Hui Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
- (2017) Aiko Nagayama et al. Targeted Oncology
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
- (2016) Bishoy Faltas et al. Clinical Genitourinary Cancer
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Antibody-drug conjugates for non-oncological indications
- (2016) Renhe Liu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Prospects and progress of antibody-drug conjugates in solid tumor therapies
- (2016) Serengulam V. Govindan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
- (2016) Alain Beck et al. Expert Review of Proteomics
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
- (2016) M. Dorywalska et al. MOLECULAR CANCER THERAPEUTICS
- Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
- (2016) C.-H. Chang et al. MOLECULAR CANCER THERAPEUTICS
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro
- (2016) Guillaume Brachet et al. MOLECULAR PHARMACEUTICS
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Processes for Constructing Homogeneous Antibody Drug Conjugates
- (2016) David Y. Jackson ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
- (2015) Wayne C. Widdison et al. BIOCONJUGATE CHEMISTRY
- Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate
- (2015) Reyna K. V. Lim et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
- (2015) K. J. Hamblett et al. CANCER RESEARCH
- Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC)
- (2015) João P. M. Nunes et al. CHEMICAL COMMUNICATIONS
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
- (2015) Giulio Casi et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Immunosuppressive Antibody–Drug Conjugate
- (2015) Rongsheng E. Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Noninternalizing Targeted Cytotoxics for Cancer Therapy
- (2015) Giulio Casi et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Homed to the hideout
- (2015) Wolf-Dietrich Hardt NATURE
- Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
- (2015) Sophie M. Lehar et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- An Anti-CD79B Antibody-Drug Conjugate Is Active in Non-Hodgkin Lymphoma
- (2015) Cancer Discovery
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
- (2014) George Badescu et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging
- (2014) Sam Massa et al. BIOCONJUGATE CHEMISTRY
- Versatility of Microbial Transglutaminase
- (2014) Pavel Strop BIOCONJUGATE CHEMISTRY
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema
- (2014) J. A. Carlson et al. NEURO-ONCOLOGY
- Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
- (2014) Felix F. Schumacher et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Risks and untoward toxicities of antibody-based immunoconjugates
- (2012) Dana Litvak-Greenfeld et al. ADVANCED DRUG DELIVERY REVIEWS
- Highly efficient disulfide bridging polymers for bioconjugates from radical-compatible dithiophenol maleimides
- (2012) Mathew W. Jones et al. CHEMICAL COMMUNICATIONS
- Antibody–drug conjugates: Basic concepts, examples and future perspectives
- (2012) Giulio Casi et al. JOURNAL OF CONTROLLED RELEASE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone
- (2012) Jonas H Graversen et al. MOLECULAR THERAPY
- Cancer stromal targeting (CAST) therapy
- (2011) Yasuhiro Matsumura ADVANCED DRUG DELIVERY REVIEWS
- Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue
- (2011) Masahiro Yasunaga et al. BIOCONJUGATE CHEMISTRY
- New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots
- (2011) Masahiro Yasunaga et al. CANCER SCIENCE
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Les immunoconjugués, anticorps « armés » pour combattre le cancer
- (2011) Jean-François Haeuw et al. M S-MEDECINE SCIENCES
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More